AGR2 and ovarian cancer: The purpose of this study was to characterise changes in the plasma concentrations of MDK in association with ovarian cancer and compare its diagnostic performance (as assessed by the AUC) with that of AGR2 (a recently reported circulating biomarker of ovarian cancer [11]) and CA125 in symptomatic women.